1. 170P EO2401 microbiome derived therapeutic vaccine + nivolumab +/- bevacizumab, in neoadjuvant, adjuvant and non-surgery linked treatment of recurrent glioblastoma: Phase I-II EOGBM1-18/ROSALIE study. (December 2022) Authors: Wick, W.; IdBaih, A.; Vieito Villar, M.; Tabatabai, G.; Stradella, A.; Ghiringhelli, F.; Burger, M.; Mildenberger, I.; Herrlinger, U.; Touat, M.; Wen, P.; Wick, A.; Gouttefangeas, C.; Maia, A.; Bonny, C.; Paillarse, J-M.; Fagerberg, J.; Reardon, D.A. Journal: Immuno-oncology technology Issue: Volume 16(2022)Supplement 1 Page Start: Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
2. 185P Interim analysis of the EOGBM1-18 study: Strong immune response to therapeutic vaccination with EO2401 microbiome derived therapeutic vaccine + nivolumab. (December 2022) Authors: Wick, W.; Gamelas Magalhaes, J.; Dos Santos Leite, A.M.; IdBaih, A.; Vieito Villar, M.; Tabatabai, G.; Stradella, A.; Ghiringhelli, F.; Burger, M.; Mildenberger, I.; Herrlinger, U.; Touat, M.; Wen, P.; Wick, A.; Toussaint, H.; Gouttefangeas, C.; Bonny, C.; Paillarse, J-M.; Reardon, D.A. Journal: Immuno-oncology technology Issue: Volume 16(2022)Supplement 1 Page Start: Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
3. ADHERENCE TO ORAL ANTICANCER THERAPIES IN A CLINICAL CANCER CENTRE. (November 2019) Authors: De Gregori, J.; Coudert, B.; Desmoulins, I.; Favier, L.; Isambert, N.; Zanetta, S.; Ghiringhelli, F.; Vincent, J.; Ladoire, S.; Hennequin, A.; Lagrange, A.; Hervieu, A.; Di Martino, C.; Gallet, M.; Quipourt, V.; Lefevre, L.Bengrine; Schmitt, A. Journal: Journal of geriatric oncology Issue: Volume 10(2019)Supplement 1 Page Start: S86 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
4. Continuation versus discontinuation of first-line chemotherapy in patients with metastatic squamous cell oesophageal cancer: A randomised phase II trial (E-DIS). (April 2019) Authors: Adenis, A.; Bennouna, J.; Etienne, P.L.; Bogart, E.; Francois, E.; Galais, M.P.; Ben Abdelghani, M.; Michel, P.; Metges, J.P.; Dahan, L.; Conroy, T.; Ghiringhelli, F.; Drouillard, A.; El Hajbi, F.; Samalin, E.; Hiret, S.; Delaine-Clisant, S.; Mariette, C.; Penel, N.; Piessen, G. Journal: European journal of cancer Issue: Volume 111(2019) Page Start: 12 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
5. Deep learning for colon cancer histopathological images analysis. (September 2021) Authors: Ben Hamida, A.; Devanne, M.; Weber, J.; Truntzer, C.; Derangère, V.; Ghiringhelli, F.; Forestier, G.; Wemmert, C. Journal: Computers in biology and medicine Issue: Volume 136(2021) Page Start: Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
6. EP-1247: Exclusive chemoradiation with Carboplatin-Taxol vs Folfox-4 in locally advanced esophageal cancer. (May 2017) Authors: Crehange, G.; Bertaut, A.; Bosset, J.F.; Boustani, J.; Rouffiac, M.; Ghiringhelli, F.; Borg, C.; De Bari, B.; Buffet Miny, J. Journal: Radiotherapy and oncology Issue: Volume 123:(2017:May)Supplement 1 Page Start: S671 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
7. FOLFIRINOX as induction treatment in rectal cancer patients with synchronous metastases: Results of the FFCD 1102 phase II trial. (November 2018) Authors: Dahan, L.; Auby, D.; Khemissa, F.; Ghiringhelli, F.; Nguyen, S.; Bedjaoui, A.; Terrebonne, E.; Thaury, J.; Baconnier, M.; Bachet, J.B.; Lucidarme, O.; Levache, C.B.; Barbier, E.; Raoul, J.L.; Lecomte, T.; Desauw, C.; Brocard, F.; Pernot, S.; Breysacher, G.; Lagasse, J.P. Journal: European journal of cancer Issue: Volume 104(2018) Page Start: 108 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
8. Immune and mutational landscape in triple negative breast cancer and its evolution during neoadjuvant chemotherapy associated or not with GTN and anti-PD-1. (March 2019) Authors: Mabrouk, N.; Racoeur, C.; Dondaine, L.; Shann, J.; Ghiringhelli, F.; Chouchane, L.; Bettaieb, A.; Paul, C. Journal: European journal of cancer Issue: Volume 110(2019)Supplement 1 Page Start: S4 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
9. In-vivo and in-vitro impact of high-dose rate radiotherapy using flattening-filter-free beams on the anti-tumor immune response. (September 2020) Authors: Laurent, P.A.; Kownacka, A.; Boidot, R.; Richard, C.; Limagne, E.; Morgand, V.; Froidurot, L.; Bonin, C.; Aubignac, L.; Ghiringhelli, F.; Créhange, G.; Mirjolet, C. Journal: Clinical and translational radiation oncology Issue: Volume 24(2020) Page Start: 116 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
10. Overweight is associated to a better prognosis in metastatic colorectal cancer: A pooled analysis of FFCD trials. (July 2018) Authors: Adenis, A.; Alessio, A.; Aouakli, A.; Azzedine, A.; Bedjaoui, A.; Bidault, A.; Blanchi, A.; Botton, A.; Cadier-Lagnes, A.; Fatisse, A.; Gagnaire, A.; Gilbert, A.; Gueye, A.; Hollebecque, A.; Lemaire, A.; Mahamat, A.; Marre, A.; Patenotte, A.; Rotenberg, A.; Roussel, A. Journal: European journal of cancer Issue: Volume 98(2018) Page Start: 1 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗